Inflazome, a Dublin, Ireland-based developer of orally available drugs, closed a Series A financing round for up to US$17/€15m.
The round was co-led by Novartis Venture Funds and Fountain Healthcare Partners. Following the closure of the financing round, Florent Gros (Managing Director of Novartis Venture Fund), and Dr. Manus Rogan (Co-Founder and Managing Director at Fountain Healthcare Partners) joined the Board of Directors.
Led by Dr. Matt Cooper, Co-Founder and CEO, and Prof. Luke O’Neill, Co-Founder and CSO, Inflazome is developing inhibitors of the inflammasome, a biological target that regulates innate immune response, now associated with a wide variety of diseases.
Joining the founding management team as VP of Business Development is Dr. Jeremy Skillington, formally of Genentech.